Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick RedHill/IntelGenx FDA response fails to impress investors

This article was originally published in Scrip

Executive Summary

The relatively quick response by RedHill Biopharma and its partner IntelGenx to the FDA's 4 February complete response letter (CRL) for the companies' new drug application (NDA) for RHB-103, an oral thin film formulation of rizatriptan benzoate, a 5-HT1 agonist, which is under investigation as a treatment for acute migraines, did little to stir excitement among investors on 3 March.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts